Loading stock data…
EWTX
$34.06-0.78 (-2.24%)
After Hours$34.06+0.00 (+0.00%)· Last close Jun 9
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Edgewise Therapeutics, Inc. in the Healthcare sector is trading at $34.06 with a market capitalization of $3.7B. Wall Street consensus targets $46.08 (12 analysts), implying a +35.3% move over the next 12 months. The stock is currently 16% below its 52-week high of $40.77, remaining 34.7% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +35.3% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$34.06
Potential Downside
0%
Whystock Fair Value$34.06
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus12 analysts
Buy
Mean target$46.08+35.3%
Range$20.00 – $66.00
Fundamentals
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II clini...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$3.68B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.25
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-35.69%
Volume
Today's trading volume
1.21M
Recent News
Assessing Edgewise Therapeutics (EWTX) Valuation After A Sharp Recent Share Price Move
Recent Stock Move Puts Edgewise Therapeutics In Focus Edgewise Therapeutics (EWTX) has drawn fresh attention after recent share gains, with the stock up over the past day, week, month and past 3 months, prompting investors to reassess the company’s muscle disorder pipeline. See our latest analysis for Edgewise Therapeutics. The recent 1-day share price return of 17.86% at a latest share price of $40.26 builds on strong momentum, with a 30-day share price return of 31.53% and a 1-year total...
Edgewise Therapeutics Stock Hits Record High on $2.65B Servier Deal
EWTX surges 18% to a record high after striking a $2.65 billion neuromuscular business divestiture deal with Servier, sharpening focus on its cardiovascular pipeline.
Servier to acquire Edgewise’s muscular dystrophy business for $2.65bn
The companies anticipate finalising the acquisition in the third quarter of 2026.
How Edgewise Sweetened Its Coffers By $1.55 Billion, And Removed A Key Overhang
Edgewise Therapeutics stock rocketed Monday after Servier agreed to buy the biotech's muscular dystrophy business for up to $2.65 billion.
EWTX Stock Hits Record High – Why Servier Is Shelling Out $2.65B For Edgewise’s Muscular Dystrophy Business
Under the agreement, Servier will pay $1.55 billion upfront, with up to an additional $1.1 billion tied to regulatory and commercial milestones.